
<!DOCTYPE html>
<html lang="en">
<head>
<!-- Meta-Tag -->
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

<title>TolsuraHCP</title>

<meta name="apple-mobile-web-app-status-bar-style" content="#cd9f26">
<meta name="theme-color" content="#cd9f26" />

<!-- googlefont -->
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,400;0,600;0,700;1,400;1,600;1,700&display=swap" rel="stylesheet">

<!-- favicon -->
<link rel="icon" href="assets/img/favicon.ico">

<!-- CSS -->
<link rel="stylesheet" href="assets/css/bootstrap.min.css">
<link rel="stylesheet" href="assets/css/style.css">
</head>
<body class="infection-overview">
<!-- Announcement Bar Start -->
<div class="announcement__bar text-center text-white pt-lg-3 pb-lg-3 pt-2 pb-2">
    <div class="container">
        <div class="d-flex justify-content-center align-items-center">
            <div class="announcement__title"><strong>JOIN US FOR A SPECIAL WEBINAR</strong> ABOUT OUR BREAKTHROUGH ANTIFUNGAL INNOVATION, TOLSURA</div>
            <a href="#" class="btn btn-transparent"><span class="d-none d-lg-block">REGISTER TO JOIN</span><img class="d-block d-lg-none" src="assets/img/icons-arrow_right.svg" alt="Icons Arrow Right"> </a>
        </div>
    </div>
</div>
<!-- Announcement Bar End -->

<!-- HEADER START -->
<header>
    <div class="container">
        <div class="d-flex align-items-center">
            <a class="nav__toggle" href="#" aria-label="Toggle navigation"><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span></a>
            <a href="index.html" class="logo"><img src="assets/img/TOLSURA_DARK_LOGO.png" alt="Go To Tolsura"></a>
            <div class="nav__block flex-column">
                <div class="nav-wrapper d-flex flex-lg-column-reverse">
                    <div class="primary__nav">
                        <ul>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item current_page_item"><a href="#">INFECTIONS OVERVIEW</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="abouttolsura.html">ABOUT TOLSURA</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children"><a href="#">BENEFITS OF TOLSURA</a>
                                <ul>
                                    <li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item current_page_item"><a href="#">BIOAVAILABILITY</a></li>
                                    <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="#">ABSORPTION</a></li>
                                    <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="#">THERAPEUTIC LEVELS</a></li>
                                </ul>
                            </li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="safety.html">SAFETY</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="dosing.html">DOSING</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="savings.html">SAVINGS</a></li>
                        </ul>
                    </div>
                    <div class="secondary__nav mb-md-3">
                        <ul>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="#isi-expand">Important Safety Information</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="#">Prescribing Information</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="#">Patient Site</a></li>
                        </ul>
                    </div>
                </div>
            </div>
            <div class="ml-auto">
                <a class="btn" data-toggle="modal" data-target="#myModal">Contact A Representative</a>
            </div> 
        </div>
    </div>
</header>
<!-- HEADER END -->

<!-- BANNER SECTION START -->
<section class="page__banner" style="background-image: url(assets/img/Aspergillosis_triangle_graphic.png);">
    <div class="container">
        <div class="page__banner-description">
            <h1>Histoplasmosis, Blastomycosis and Aspergillosis: An Overview</h1>
            <p>Systemic fungal infections, including endemic infections may be difficult to diagnose and can be challenging to treat. Learn more about these disease states and their treatment by itraconazole.</p>
            <div class="btn-row">
                <a href="#histoplasmosis" class="btn">HISTOPLASMOSIS</a>
                <a href="#blastomycosis" class="btn">BLASTOMYCOSIS</a>
                <a href="#aspergillosis" class="btn">ASPERGILLOSIS</a>
            </div>
        </div>
    </div>
</section>
<!-- BANNER SECTION END -->

<!-- skip to content link start -->
<a class="sr-only skip-link screen-reader-text" href="#maincontent">Skip to the content</a>
<!-- skip to content link end -->

<!-- PAGE CONTENT START -->
<main id="maincontent" class="pagecontent">
  <!-- HISTOPLASMOSIS SECTION START -->
  <div class="section infection__article pt-100" id="histoplasmosis">
    <div class="primary__title pb-100">
        <div class="container">
            <h2>HISTOPLASMOSIS</h2>
        </div>
    </div>
    <div class="infection__card pb-100">
        <div class="container">
            <h3>AREA ENDEMIC FOR INFECTION:</h3>
            <div class="row">
                <div class="col-lg-6">
                    <div class="card__wrapper">
                        <img class="triangle" src="assets/img/Triangle-gray.svg" alt="Traingle Gray">
                        <div class="card__img position-relative">
                            <img class="img-fluid" src="assets/img/HISTOPLASMOSIS.png" alt="HISTOPLASMA">
                        </div>
                        <div class="card__description d-flex justify-content-between">
                            <div class="card__title">
                                <h4>HISTOPLASMA</h4>
                            </div>
                            <div class="card__badge position-relative">
                                <p>Common</p>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="region__img mt-lg-0 mt-5">
                        <img class="img-fluid" src="assets/img/Histoplasma_endemic-region.svg" alt="Histoplasma Endemic Region">
                    </div>
                </div>
            </div>
        </div>
    </div>
    <div class="infection__info">
        <div class="container">
            <h2>IDSA RECOMMENDS ITRACONAZOLE FOR HISTOPLASMOSIS<sup>1,2</sup></h2>
            <h3>IDSA guidelines describe using antifungals, including itraconazole, for treating cases of histoplasmosis.</h3>
            <div class="infection__table">
                <h4>HISTOPLASMOSIS</h4>
                <div class="treatment__guideline">
                    <table>
                        <tr>
                            <th class="blue__bg text-white" colspan="2"><span class="ex1">IDSA GUIDELINES FOR TREATING HISTOPLASMOSIS</span></th>
                        </tr>
                        <tr>
                            <th class="blue__bg text-white">Manifestation</th>
                            <th class="blue__bg text-white">Treatment</th>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">Acute pulmonary histoplasmosis</th>
                        </tr>
                        <tr>
                            <td><strong>Mild to moderate</strong></td>
                            <td>200 mg itraconazole OD or BID for 6-12 weeks for patients who continue to have symptoms for >1 month</td>
                        </tr>
                        <tr>
                            <td><strong>Moderately severe to severe</strong></td>
                            <td>200 mg itraconazole BID for a total of 12 weeks following 1-2 weeks of Amphotericin B</td>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">Chronic cavitary pulmonary histoplasmosis</th>
                        </tr>
                        <tr>
                            <td>&nbsp;</td>
                            <td>Loading dose of 200 mg itraconazole TID for the first 3 days, followed by 200 mg itraconazole OD or BID for 6-12 weeks for at least 12 months</td>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">Pericarditis</th>
                        </tr>
                        <tr>
                            <td><strong>Moderately severe to severe</strong></td>
                            <td>200 mg itraconazole OD or BID for 6-12 weeks if prednisone used</td>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">Mediastinal granuloma</th>
                        </tr>
                        <tr>
                            <td><strong>Symptomatic</strong></td>
                            <td>200 mg itraconazole OD or BID for 6-12 weeks</td>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">Progressive disseminated histoplasmosis</th>
                        </tr>
                        <tr>
                            <td><strong>Mild to moderate</strong></td>
                            <td>200 mg itraconazole BID for at least 12 months</td>
                        </tr>
                        <tr>
                            <td><strong>Moderately severe to severe</strong></td>
                            <td>200 mg itraconazole BID for at least 12 months following 1-2 weeks of Amphotericin B</td>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">CNS histoplasmosis</th>
                        </tr>
                        <tr>
                            <td><strong>Mild to moderate</strong></td>
                            <td>200 mg itraconazole BID or TID for at least 12 months following 1-2 weeks of Amphotericin B</td>
                        </tr>
                    </table>
                </div>
            </div>
            <div class="article__treatment pt-100 pb-100">
                <h2>WHEN HISTOPLASMOSIS PATIENTS WERE TREATED WITH ORAL ITRACONAZOLE<sup>3</sup>:</h2>
                <div class="row">
                    <div class="col-md-4 mb-3">
                        <div class="article__wrapper">
                            <h3>81%</h3>
                            <h4>ACHIEVED TREATMENT SUCCESS</h4>
                        </div>
                    </div>
                    <div class="col-md-4 mb-3">
                        <div class="article__wrapper">
                            <h3>86%</h3>
                            <h4>ACHIEVED TREATMENT SUCCESS WHEN TREATED AT THERAPEUTIC LEVELS FOR AT LEAST 2 MONTHS</h4>
                        </div>
                    </div>
                    <div class="col-md-4 mb-3">
                        <div class="article__wrapper">
                            <h3>9 <small>MONTHS</small></h3>
                            <h4>MEDIAN DURATION TREATMENT TIME FOR PATIENTS WHO WERE CONSIDERED A SUCCESS</h4>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
  </div>
  <!-- HISTOPLASMOSIS SECTION END -->
  
  <!-- BLASTOMYCOSIS SECTION START -->
  <div class="section infection__article pt-100" id="blastomycosis">
    <div class="primary__title pb-100">
        <div class="container">
            <h2>BLASTOMYCOSIS</h2>
        </div>
    </div>
    <div class="infection__card pb-100">
        <div class="container">
            <h3>AREA ENDEMIC FOR INFECTION:</h3>
            <div class="row">
                <div class="col-lg-6">
                    <div class="card__wrapper">
                        <img class="triangle" src="assets/img/Triangle-gray.svg" alt="Traingle Gray">
                        <div class="card__img position-relative">
                            <img class="img-fluid" src="assets/img/BLASTOMYCOSIS.png" alt="BLASTOMYCOSIS">
                        </div>
                        <div class="card__description d-flex justify-content-between">
                            <div class="card__title">
                                <h4>BLASTOMYCOSIS</h4>
                            </div>
                            <div class="card__badge position-relative">
                                <p>Common</p>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="region__img mt-lg-0 mt-5">
                        <img class="img-fluid" src="assets/img/Histoplasma_endemic-region.svg" alt="Histoplasma Endemic Region">
                    </div>
                </div>
            </div>
        </div>
    </div>
    <div class="infection__info">
        <div class="container">
            <h2>IDSA RECOMMENDS ITRACONAZOLE FOR BLASTOMYCOSIS<sup>1,2</sup></h2>
            <h3>IDSA guidelines describe using antifungals, including itraconazole, for treating cases of blastomycosis.</h3>
            <div class="infection__table">
                <h4>BLASTOMYCOSIS</h4>
                <div class="treatment__guideline">
                    <table>
                        <tr>
                            <th class="blue__bg text-white" colspan="2"><span class="ex1">IDSA GUIDELINES FOR TREATING BLASTOMYCOSIS</span></th>
                        </tr>
                        <tr>
                            <th class="blue__bg text-white">Manifestation</th>
                            <th class="blue__bg text-white">Treatment</th>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">Pulmonary blastomycosis</th>
                        </tr>
                        <tr>
                            <td><strong>Mild to moderate</strong></td>
                            <td>200 mg itraconazole OD or BID for 6-12 months</td>
                        </tr>
                        <tr>
                            <td><strong>Moderately severe to severe</strong></td>
                            <td>200 mg itraconazole BID for a total of 12 weeks following 1-2 weeks of Amphotericin B</td>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">Disseminated blastomycosis</th>
                        </tr>
                        <tr>
                            <td><strong>Mild to moderate</strong></td>
                            <td>200 mg itraconazole BID for 6-12 months</td>
                        </tr>
                        <tr>
                            <td><strong>Moderately severe to severe</strong></td>
                            <td>200 mg itraconazole BID for 12 months following 1-2 weeks of Amphotericin B</td>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">CNS blastomycosis</th>
                        </tr>
                        <tr>
                            <td>&nbsp;</td>
                            <td>oral azole therapy for 1 year following 4-6 weeks of Amphotericin B</td>
                        </tr>
                        <tr>
                            <th class="gray-bg" colspan="2">Immunosuppressed patients</th>
                        </tr>
                        <tr>
                            <td>&nbsp;</td>
                            <td>200 mg itraconazole BID for 12 months following 1-2 weeks of Amphotericin B</td>
                        </tr>
                    </table>
                </div>
            </div>
            <div class="article__treatment pt-100 pb-100">
                <h2>WHEN BLASTOMYCOSIS PATIENTS WERE TREATED WITH ITRACONAZOLE<sup>3</sup>:</h2>
                <div class="row">
                    <div class="col-md-4 mb-3">
                        <div class="article__wrapper">
                            <h3>90%</h3>
                            <h4>ACHIEVED TREATMENT SUCCESS</h4>
                        </div>
                    </div>
                    <div class="col-md-4 mb-3">
                        <div class="article__wrapper">
                            <h3>95%</h3>
                            <h4>ACHIEVED TREATMENT SUCCESS WHEN TREATED AT THERAPEUTIC LEVELS FOR AT LEAST 2 MONTHS</h4>
                        </div>
                    </div>
                    <div class="col-md-4 mb-3">
                        <div class="article__wrapper">
                            <h3>6.2 <small>MONTHS</small></h3>
                            <h4>MEDIAN DURATION TREATMENT TIME FOR PATIENTS WHO WERE CONSIDERED A SUCCESS</h4>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
  </div>
  <!-- BLASTOMYCOSIS SECTION START -->

  <!-- GRAY SECTION START -->
  <div class="section treatment__textblock gray__bg text-center pt-100 pb-100">
    <div class="container">
        <h2>ITRACONAZOLE REMAINS THE DRUG OF CHOICE FOR TREATING HISTOPLASMOSIS AND BLASTOMYCOSIS AFTER NEARLY THREE DECADES<sup>1,2</sup></h2>
    </div>
  </div>
  <!-- GRAY SECTION END -->

  <!-- ASPERGILLOSIS SECTION START -->
  <div class="section infection__article pt-100" id="aspergillosis">
    <div class="primary__title pb-100">
        <div class="container">
          <h2>ASPERGILLOSIS</h2>
        </div>
    </div>
    <div class="infection__card pb-100">
        <div class="container">
            <h3>AREA ENDEMIC FOR INFECTION:</h3>
            <div class="row align-items-center">
                <div class="col-lg-6">
                    <div class="card__wrapper">
                        <img class="triangle" src="assets/img/Triangle-gray.svg" alt="Traingle Gray">
                        <div class="card__img position-relative">
                            <img class="img-fluid" src="assets/img/ASPERGILLOSIS.png" alt="ASPERGILLOSIS">
                        </div>
                        <div class="card__description d-flex justify-content-between">
                            <div class="card__title">
                            <h4>ASPERGILLOSIS</h4>
                            </div>
                            <div class="card__badge position-relative">
                                <p>Common</p>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="region__img mt-lg-0 mt-5">
                        <img class="img-fluid mb-5" src="assets/img/Histoplasma_endemic-region.svg" alt="Histoplasma Endemic Region">
                        <p><strong>Aspergillosis</strong> is a non-endemic, opportunistic mold infection that is common across the US<sup>4</sup>.</p>
                        <p>The causative fungi, <em>Aspergillus</em>, is a common mold found both indoors and outdoors. While not contained to a certain geographic area, <em>Aspergillus</em> continues to be a cause of life-threatening infections in patients.</p>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <div class="infection__info">
        <div class="container">
            <h2>IDSA AND ATS RECOMMEND ITRACONAZOLE FOR ASPERGILLOSIS<sup>1,2</sup></h2>
            <h3>IDSA and ATS guidelines describe using antifungals, including itraconazole, for treating cases of aspergillosis.</h3>
            <div class="infection__table">
                <h4>ASPERGILLOSIS</h4>
                <div class="treatment__guideline">
                    <table>
                        <tbody><tr>
                            <th class="blue__bg text-white" colspan="3"><span class="ex1">US CLINICAL GUIDELINES FOR THE TREATMENT <br>OF ASPERGILLOSIS SYNDROMES:</span></th>
                        </tr>
                        <tr>
                            <th class="blue__bg text-white border-right">Disease Manifestation</th>
                            <th class="blue__bg text-white border-right">Treatment Recommendation (ATS)</th>
                            <th class="blue__bg text-white">Treatment Recommendation (IDSA)</th>
                        </tr>
                        <tr>
                            <td style="width: 25%; padding: 20px;">Chronic necrotizing (‘‘semi-invasive’’) pulmonary aspergillosis</td>
                            <td style="padding: 20px;">200 mg <strong class="font-weight-bold">itraconazole</strong> TID for 3 days and then OD or BID for at least 12 months, but some prefer 18-24 months in view of the risk for relapse (Strength of Recommendation A, Quality of Evidence II)</td>
                            <td style="width: 30%; padding: 20px;"><strong class="font-weight-bold">Itraconazole</strong> alternative therapy option</td>
                        </tr>
                        <tr>
                            <td style="width: 25%; padding: 20px;">Allergic bronchopulmonary aspergillosis</td>
                            <td style="padding: 20px;"><strong class="font-weight-bold">Itraconazole</strong> used as a steroid-sparing agent</td>
                            <td style="width: 30%; padding: 20px;"><strong class="font-weight-bold">Itraconazole</strong> as primary therapy</td>
                        </tr>
                        <tr>
                            <td style="width: 25%; padding: 20px;">Invasive aspergillosis</td>
                            <td style="padding: 20px;">Primary Therapy: IV voriconazole until improvement followed by oral voriconazole OR oral <strong class="font-weight-bold">itraconazole</strong> until resolution or stabilization of all clinical and radiographic manifestations</td>
                            <td style="width: 30%; padding: 20px;"><strong class="font-weight-bold">Itraconazole</strong> alternative therapy option</td>
                        </tr>
                    </tbody></table>
                </div>
            </div>
            <div class="treatment__comparison pt-100 pb-100">
                <h3>ITRACONAZOLE FOR THE TREATMENT OF ASPERGILLOSIS</h3>
                <div class="row">
                    <div class="col-lg-6 mb-lg-0 mb-5">
                        <h4>WHEN CHRONIC ASPERGILLOSIS PATIENTS WERE TREATED WITH <br class="hide-m">ORAL ITRACONAZOLE <sup>5</sup>:</h4>
                        <div class="treatment__description--col d-flex flex-md-row flex-column justify-content-md-between align-items-md-center mb-md-5 mb-3 pb-md-5 pb-3">
                            <h5>63%</h5>
                            <h6>global improvement in aspergilloma<sup>5</sup></h6>
                        </div>
                        <div class="treatment__description--col d-flex flex-md-row flex-column justify-content-md-between align-items-md-center mb-md-5 mb-3 pb-md-5 pb-3">
                            <h5>71%</h5>
                            <h6>improvement or stabilization of clinical and mycologic features with long term therapy in CPA<sup>7</sup></h6>
                        </div>
                        <div class="treatment__description--col d-flex flex-md-row flex-column justify-content-md-between align-items-md-center">
                            <h5>93%</h5>
                            <h6>improvement in clinical and radiological features for Chronic Necrotizing Pulmonary Aspergillosis<sup>8</sup></h6>
                        </div>
                    </div>
                    <div class="col-lg-6">
                        <h4>AFTER 6 MONTHS OF ORAL ITRACONAZOLE TREATMENT IN <br class="hide-m">CCPA PATIENTS<sup>6</sup>:</h4>
                        <div class="treatment__description--col d-flex flex-md-row flex-column justify-content-md-between align-items-md-center mb-md-5 mb-3 pb-md-5 pb-3">
                            <h5>77%</h5>
                            <h6>had improved overall response</h6>
                        </div>
                        <div class="treatment__description--col d-flex flex-md-row flex-column justify-content-md-between align-items-md-center mb-md-5 mb-3 pb-md-5 pb-3">
                            <h5>76%</h5>
                            <h6>had a stable to improved clinical responses</h6>
                        </div>
                        <div class="treatment__description--col d-flex flex-md-row flex-column justify-content-md-between align-items-md-center">
                            <h5>76%</h5>
                            <h6>had a stable to improved radiological response</h6>
                        </div>
                    </div>
                </div>
            </div>
            <div class="treatment__response pt-100 pb-100">
                <div class="row">
                    <div class="col-lg-5 pt-lg-5 mt-lg-4">
                        <h2>OVERALL RESPONSE IN PATIENTS AFTER 6 MONTHS OF ITRACONAZOLE TREATMENT</h2>
                    </div>
                    <div class="col-lg-7">
                        <div class="treatment__chart d-flex justify-content-lg-end justify-content-center align-items-md-end mt-lg-0 ml-auto">
                            <ul>
                                <li class="green-color">Improved</li>
                                <li class="gray-color">Not Improved</li>
                            </ul>
                            <img class="img-fluid" src="assets/img/Itraconazole-treatment.png" alt="Itraconazole Treatment">
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
  </div>
  <!-- ASPERGILLOSIS SECTION END -->

  <!-- FUNGAL INFECTION SECTION START -->
  <div class="section infection__section pb-100">
    <div class="primary__title pb-100">
        <div class="container">
            <div class="row">
                <div class="col-lg-10">
                    <h2>FUNGAL INFECTIONS POSE A SIGNIFICANT THREAT FOR SOME PATIENTS<sup>9</sup></h2>
                </div>
            </div>
        </div>
    </div>
    <div class="infection__types mt-lg-0 mt-5">
        <div class="container">
            <div class="row">
                <div class="col-lg-4">
                    <div class="infection__wrapper border-right text-center">
                        <div class="person__img"><img class="img-fluid" src="assets/img/Patient-graphic.svg" alt="Fungal Infection Type 1"></div>
                        <div class="infection__description">
                         <p>Many patients may be exposed to the fungi without ever presenting symptoms<sup>10, 11</sup>.</p>
                         </div>
                    </div>
                </div>
                <div class="col-lg-4">
                    <div class="infection__wrapper text-center">
                        <div class="person__img"><img class="img-fluid" src="assets/img/Patient-symptoms-graphic.svg" alt="Fungal Infection Type 2"></div>
                        <div class="infection__description"><p>Patients may present with persistent cough, sepsis or persistent fever (despite antibiotics), pulmonary infiltrates, nodular skin lesions, and other signs<sup>12</sup>.</p></div>
                    </div>
                </div>
                <div class="col-lg-4">
                    <div class="infection__wrapper border text-center">
                        <img class="img-fluid info-icon" src="assets/img/info-icon.svg" alt="Info Icon">
                        <div class="more-info"><h3>FOR MORE INFORMATION:</h3></div>
                        <div class="btn-row d-flex flex-column">
                            <a href="#" class="btn mb-4">Infectious Diseases Society of America</a>
                            <a href="#" class="btn mb-4">American Thoracic Society</a>
                            <a href="#" class="btn">Centers for Disease Control and Prevention</a>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
  </div>
  <!-- FUNGAL INFECTION SECTION END -->

  <!-- PATIENT DISEASES SECTION START -->
  <div class="section dieseas pt-100 pb-100">
    <div class="primary__title pb-100">
        <div class="container">
            <div class="row">
                <div class="col-xl-7 col-lg-9">
                  <h2>IMMUNOCOMPETENT AND IMMUNOCOMPROMISED PATIENTS MAY BE AT RISK<sup>9,13</sup>:</h2>
                </div>
            </div>
        </div>
    </div>
    <div class="disease__list mt-lg-0 mt-5">
        <div class="container">
            <ul>
                <li>Organ transplant</li>
                <li>Chemotherapy</li>
                <li>Hematopoietic stem cell transplant</li>
                <li>High-dose corticosteroids</li>
                <li>HIV/AIDS</li>
                <li>Prolonged antibiotic therapy</li>
                <li>Hematologic malignancies</li>
                <li>TPN = total parenteral nutrition (IV nutrition)</li>
                <li>Surgery</li>
                <li>ESRD = end-stage renal disease (kidney failure)</li>
                <li>ICU stay</li>
                <li>Mechanical ventilation</li>
            </ul>
        </div>
    </div>
  </div>
  <!-- PATIENT DISEASES SECTION END -->

  <!-- TABLET FEATURES SECTION START -->
  <div class="section tablet__features pt-100 pb-100">
    <div class="primary__title pb-100">
        <div class="container">
            <div class="row">
                <div class="col-xl-9 col-lg-12">
                 <h2>CHALLENGES AND LIMITATIONS WITH CONVENTIONAL ITRACONAZOLE</h2>
                </div>
            </div>
        </div>
    </div>
    <div class="table__features-container mt-lg-0 mt-5">
        <div class="container">
            <div class="row">
                <div class="col-lg-6 mb-lg-0 mb-5">
                    <div class="tablet__features-card d-flex flex-column gray__bg">
                        <div class="title-row d-flex justify-content-between mb-5">
                            <h3>Sporanox® 100 mg Capsules<sup>14</sup></h3>
                            <img src="assets/img/SpornoxCapsule.svg" alt="Sporanox Capsule">
                        </div>
                        <div class="tablet__features-list">
                            <ul>
                                <li>
                                    <div class="left-col">Bioavailability</div>
                                    <div class="right-col">55%</div>
                                </li>
                                <li>
                                    <div class="left-col">Food effect on bioavailability</div>
                                    <div class="right-col">40% decrease when taken without food</div>
                                </li>
                                <li>
                                    <div class="left-col">Effect of PPIs on bioavailability</div>
                                    <div class="right-col">68% decrease when taken with omeprazole<sup>17</sup></div>
                                </li>
                                <li>
                                    <div class="left-col">Inter-Patient variability<sup>14,16</sup></div>
                                    <div class="right-col">High</div>
                                </li>
                                <li>
                                    <div class="left-col">Absorption variability<sup>16,18</sup></div>
                                    <div class="right-col">
                                        <ul>
                                            <li>Vary by as much as 15-fold depending on pH of gastric environment</li>
                                            <li>Requires stomach-acid to release drug, but precipitates in higher pH of intestines</li>
                                        </ul>
                                    </div>
                                </li>
                                <li>
                                    <div class="left-col">Patient adherence<sup>22</sup></div>
                                    <div class="right-col">-</div>
                                </li>
                            </ul>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="tablet__features-card d-flex flex-column gray__bg">
                        <div class="title-row d-flex justify-content-between mb-5">
                            <h3>Sporanox® Oral Solution</h3>
                            <img src="assets/img/SpornoxOralSolution.svg" alt="Sporanox Oral Solution">
                        </div>
                        <div class="tablet__features-list">
                            <ul>
                                <li>
                                    <div class="left-col">Bioavailability</div>
                                    <div class="right-col">72%<sup>23</sup></div>
                                </li>
                                <li>
                                    <div class="left-col">Food effect on bioavailability</div>
                                    <div class="right-col">25% decrease when taken with food<sup>17</sup></div>
                                </li>
                                <li>
                                    <div class="left-col">Effect of PPIs on bioavailability</div>
                                    <div class="right-col">-</div>
                                </li>
                                <li>
                                    <div class="left-col">Inter-Patient variability<sup>14,16</sup></div>
                                    <div class="right-col">High</div>
                                </li>
                                <li>
                                    <div class="left-col">Absorption variability<sup>16,18</sup></div>
                                    <div class="right-col">-</div>
                                </li>
                                <li>
                                    <div class="left-col">Patient adherence<sup>22</sup></div>
                                    <div class="right-col">Palatability issues</div>
                                </li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
  </div>
  <!-- TABLET FEATURES SECTION END -->

    <!-- TABLET DIFFERENCE SECTION START -->
    <div class="section tablet__difference pt-100 pb-100">
        <div class="primary__title pb-100">
            <div class="container">
                <div class="row">
                    <div class="col-xl-8 col-lg-12">
                     <h2>TOLSURA ADDRESSES CHALLENGES AND LIMITATIONS WITH CONVENTIONAL ITRACONAZOLE</h2>
                    </div>
                </div>
            </div>
        </div>
        <div class="tablet__difference-list mt-5">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6">
                        <div class="feature__list red">
                            <h3>CONVENTIONAL ITRACONAZOLE</h3>
                            <ul>
                                <li>No advanced delivery technology<sup>14,15</sup></li>
                                <li>Poor bioavailability<sup>14</sup></li>
                                <li>Affected by food<sup>14,15</sup></li>
                                <li>Affected by co-administration with PPI<sup>14</sup></li>
                                <li>Requires low pH (e.g., acidic stomach) to release and absorb drug<sup>16,17</sup></li>
                                <li>Precipitates in higher pH of intestines<sup>16,17</sup></li>
                                <li>High absorption variability<sup>16,18</sup></li>
                                <li>High patient variability<sup>18</sup></li>
                            </ul>
                        </div>
                    </div>
                    <div class="col-lg-6">
                        <div class="feature__list green">
                            <h3>TOLSURA</h3>
                            <ul>
                                <li>Unique <strong>SU</strong>per<strong>B</strong>io<strong>A</strong>vailable® delivery technology<sup>19</sup></li>
                                <li><strong>~ 2x greater</strong> relative bioavailability<sup>20</sup></li>
                                <li>Maintained similar therapeutic C<sub>trough</sub> levels <strong>in fed and fasted states</strong><sup>21</sup></li>
                                <li><strong>Absorption not reduced</strong> by co-administration with PPI<sup>17,21</sup></li>
                                <li><strong>Does not rely on an acidic stomach</strong> for dissolution due to SUBA® technology<sup>17,20</sup></li>
                                <li><strong>Improved solubility</strong> in higher pH of intestines<sup>17,20</sup></li>
                                <li><strong>Improved absorption</strong> due to improved solubility<sup>17,20</sup></li>
                                <li><strong>Maintains</strong> therapeutic levels<sup>19</sup></li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <!-- TABLET DIFFERENCE SECTION END -->

    

    <!-- SUBA SCIENCE SECTION START -->
    <div class="section suba-science green__bg">
        <img class="traingle-marker img-fluid" src="assets/img/triangle.svg" alt="Traingle Marker">
        <div class="container">
            <div class="d-flex align-items-center justify-content-lg-between flex-lg-row flex-column text-white">
                <h2>THE SCIENCE OF SUBA®</h2>
                <a class="watch-video position-relative" href="#" data-toggle="modal" data-target="#myVideo">
                    <img src="assets/img/Triangle-white.svg" alt="Watch Video"> WATCH MECHANISM OF ACTION VIDEO
                </a>
            </div>
        </div>
    </div>
    <div class="section suba-cta" style="background-image: url(assets/img/suba-cta.png);"></div>
    <div class="modal" id="myVideo">
        <div class="modal-dialog video modal-dialog-centered">
          <div class="modal-content">
            <button type="button" class="close" data-dismiss="modal"><img src="assets/img/Icons_close-white.svg" alt="close"></button>
            <div class="modal-body">
                <script src="https://fast.wistia.com/embed/medias/jqf8u63qgs.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jqf8u63qgs videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/jqf8u63qgs/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" aria-hidden="true" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
            </div>
          </div>
        </div>
      </div>
    <!-- SUBA SCIENCE SECTION END -->

  <!-- Contact Modal -->
  <div class="modal" id="myModal">
    <div class="modal-dialog modal-lg">
      <div class="modal-content p-4">
        <!-- Modal Header -->
        <div class="modal-header">
          <button type="button" class="close" data-dismiss="modal"><img src="assets/img/Icons_close.svg" alt="close"></button>
          <div class="form-title" id="form-title">
             INTERESTED IN STARTING YOUR JOURNEY WITH TOLSURA?
             <span class="form-sub-title">
                Sign up for an introductory conversation with one of our representatives
             </span>
          </div>
        </div>
        
        <!-- Modal body -->
        <div class="modal-body">
           <form id="contact-form-popup" method="post">
             <div class="container">
                <div class="row">
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="firstname">First and Last Name*</label>
                         <input type="text" class="form-control" id="firstname" name="firstname" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="phone">Phone*</label>
                         <input type="text" pattern="[0-9]{1}[0-9]{9}" class="form-control" id="phone"  name="phone" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="jobtitle">Job Title*</label>
                         <div class="controlselect">
                             <select name="jobtitle" id="jobtitle" class="form-control" required="required">
                                 <option value="" selected disabled>Please select</option>
                                 <option value="Doctor of Medicine">Doctor of Medicine</option>
                                 <option value="Doctor of Osteopathy">Doctor of Osteopathy</option>
                                 <option value="Nurse Practitioner">Nurse Practitioner</option>
                                 <option value="Physician Assistant">Physician Assistant</option>
                                 <option value="Medical Assistant">Medical Assistant</option>
                                 <option value="Admin">Admin</option>
                                 <option value="Other">Other</option>
                             </select>
                         </div>
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="address">Address*</label>
                         <input type="text" class="form-control" id="address"  name="address" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="specialty">Specialty*</label>
                         <div class="controlselect">
                             <select name="specialty" id="specialty" class="form-control" required="required">
                               <option value="" selected disabled>Please select</option>
                               <option value="Infectious Disease">Infectious Disease</option>
                               <option value="Pulmonary Disease">Pulmonary Disease</option>
                               <option value="Internal Medicine">Internal Medicine</option>
                               <option value="Family Medicine">Family Medicine</option>
                               <option value="Hematology/Oncology">Hematology/Oncology</option>
                               <option value="Other">Other</option>
                             </select>
                         </div>
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="city">City*</label>
                         <input type="text" class="form-control" id="city"  name="city" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="email">Email*</label>
                         <input type="email" class="form-control" id="email"  name="email" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="row">
                         <div class="col-md-6">
                            <div class="form-group">
                               <label for="zip">ZIP*</label>
                               <input type="text" class="form-control" id="zip"  name="zip" required="required">
                             </div>
                         </div>
                         <div class="col-md-6">
                            <div class="form-group">
                               <label for="state">State*</label>
                               <div class="controlselect">
                                 <select name="state" id="state" class="form-control" required="required">
                                     <option value="" selected disabled>Please select</option>
                                       <option value="CA">California</option>
                                       <option value="CO">Colorado</option>
                                       <option value="CT">Connecticut</option>
                                       <option value="DC">Washington DC</option>
                                       <option value="DE">Delaware</option>
                                       <option value="FL">Florida</option>
                                       <option value="GA">Georgia</option>
                                       <option value="IA">Iowa</option>
                                       <option value="ID">Idaho</option>
                                       <option value="IL">Illinois</option>
                                       <option value="IN">Indiana</option>
                                       <option value="KS">Kansas</option>
                                       <option value="KY">Kentucky</option>
                                       <option value="LA">Louisiana</option>
                                       <option value="MA">Massachusetts</option>
                                       <option value="MD">Maryland</option>
                                       <option value="ME">Maine</option>
                                       <option value="MI">Michigan</option>
                                       <option value="MN">Minnesota</option>
                                       <option value="MO">Missouri</option>
                                       <option value="MS">Mississippi</option>
                                       <option value="MT">Montana</option>
                                       <option value="NC">North Carolina</option>
                                       <option value="ND">North Dakota</option>
                                       <option value="NE">Nebraska</option>
                                       <option value="NH">New Hampshire</option>
                                       <option value="NJ">New Jersey</option>
                                       <option value="NM">New Mexico</option>
                                       <option value="NV">Nevada</option>
                                       <option value="NY">New York</option>
                                       <option value="OH">Ohio</option>
                                       <option value="OK">Oklahoma</option>
                                       <option value="OR">Oregon</option>
                                       <option value="PA">Pennsylvania</option>
                                       <option value="RI">Rhode Island</option>
                                       <option value="SC">South Carolina</option>
                                       <option value="SD">South Dakota</option>
                                       <option value="TN">Tennessee</option>
                                       <option value="TX">Texas</option>
                                       <option value="UT">Utah</option>
                                       <option value="VA">Virginia</option>
                                       <option value="VT">Vermont</option>
                                       <option value="WA">Washington</option>
                                       <option value="WI">Wisconsin</option>
                                       <option value="WV">West Virginia</option>
                                       <option value="WY">Wyoming</option> 
                                     </select>
                               </div>
                             </div>
                         </div>
                      </div>
                      
                   </div>
                </div>
                <div class="row mt-4">
                   <div class="col-md-4 btn-warning-popup">
                      <img src="https://awareness.tolsura.com/l/153741/2021-01-20/43dkgf/153741/16111229975pdGm9Jm/warning_icon.svg" alt="warning"> This is a required field.
                   </div>
                   
                   <div class="col-md-8  text-right">
                      <span class="btn-info-popup">By clicking ‘Send' you agree to be contacted by phone by a sales representative of Mayne Pharma</span>
                      <button class="btn green-btn" onclick="formSubmit()">SEND NOW</button>
                   </div>
                </div>
             </div>
            </form>
            <!--For Thank you Part-->
            <div class="thank-you-popup text-center " id="thankyouPage">
                <div class="thank-you-msg" id="tymsg">
                    <div class="heading red-color mb-5">Thank You</div>
                    <div class="pt-4">One of our representatives will <br /> get in touch with you soon.</div>
                </div>
            </div>
        </div>
      </div>
    </div>
  </div>
</main>
<!-- PAGE CONTENT END -->

<!-- ISI BLOCK START -->
<div id="isi-expand" class="section pt-100">
    <div class="container pb-100">
        <div class="row">            
            <div class="col-md-12">
                <p>Indications and Important <br class="d-block d-lg-none d-md-none">  Safety Information  </p>
                <div class="warning-box">
                <p class="mb-0"><strong>BOXED WARNING</strong> <br /><strong>WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS</strong></p>
                <ul class="bullet1 mb-1 mt-1">
                <li>» CONGESTIVE HEART FAILURE</li>
                </ul>
                <p class="mb-1 pl-3"><strong>TOLSURA can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. </strong>If signs or symptoms of congestive heart failure occur or worsen during administration of TOLSURA, reassess the benefit and risk of continuing treatment.</p>
                <ul class="bullet1">
                    <li> » DRUG INTERACTIONS</li>
                </ul>
                <ul class="bullet2">
                    <li>Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with
                    TOLSURA because plasma concentrations of such drugs are increased, which may also increase or prolong both the
                    pharmacologic effects and/or adverse reactions to these drugs.</li>
                    <li>Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and</li>
                    <li>Co-administration with eligustat is contraindicated in subjects taking strong or moderate CYP2D6 inhibitors. </li>
                    <li>Increased plasma concentrations of some of these drugs caused by co-administration with TOLSURA can lead to QT prolongation and/or ventricular tachyarrhythmias, including occurrences of torsades de pointes, a potentially fatal arrhythmia.</li>
                </ul>
            </div>
        </div>
        <div class="col-md-12">
            <p class="mb-0"><strong>Indications and Usage</strong> </p>
            <p>TOLSURA is an azole antifungal indicated for the treatment of the following fungal infections in <strong>immunocompromised and non-immunocompromised</strong> adult patients:</p>
            <ul class="bullet2 ml-2">
                <li>Blastomycosis, pulmonary and extrapulmonary</li>
                <li>Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and</li>
                <li>Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy </li>
            </ul>
            <p class="mb-0 mb-2 mt-4"><strong>Limitations of Use:</strong></p>
            <p class="mb-0">TOLSURA is not indicated for the treatment of onychomycosis.</p>
            <p class="mb-0">TOLSURA is NOT interchangeable or substitutable with other itraconazole products.</p>
            <p class="mb-0 mb-2 mt-4"><strong>Contraindications</strong></p>
            <p class="mb-0">Co-administration with certain drugs that either affect metabolism of itraconazole or whose metabolism is affected by itraconazole Hypersensitivity to itraconazole</p>
            <p class="mb-0 mb-2 mt-4"><strong>Warnings and Precautions</strong></p>
            <ul class="bullet2 ml-2">
                <li><strong>Hepatotoxicity:</strong> Serious hepatotoxicity, including liver failure and death, were reported with the use of itraconazole. Discontinue treatment if signs of liver dysfunction occur</li>
                <li><strong>Cardiac Dysrhythmias:</strong> Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using certain drugs that are metabolized by human CYP450 enzymes concomitantly with oral itraconazole and/or other CYP3A4 inhibitors.</li>
                <li><strong>Peripheral Neuropathy:</strong> This has been reported in patients on long-term therapy with itraconazole. Monitor and promptly evaluate neurologic symptoms </li>
                <li><strong>Hearing loss:</strong> Reversible or permanent hearing loss has been reported in patients. Discontinue treatment if hearing loss occurs </li>
            </ul>
            <p class="mb-0 mb-2 mt-4"><strong>Adverse Reactions</strong></p>
            <p class="mb-4">Most common adverse reactions (incidence ≥ 1%) are nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, hypertension, abnormal hepatic function, abdominal pain, dizziness, hypokalemia, anorexia, malaise, decreased libido, somnolence, albuminuria, and impotence.</p>
            <p class="mb-4"><strong>To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at <a href="tel:+18448258500">1-844-825-8500</a> or the FDA at 1-800-FDA-1088 or <a target="_blank" href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program"><u>www.fda.gov/medwatch.</u></a></strong></p>
            <p class="mb-0"><strong>For more information, please see full <a class="underline" target="_blank" href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=306352d1-9d5a-49ad-b72d-893b99546861&audience=professional"><u>Prescribing Information and Patient Information Leaflet.</u> </a></strong></p>
        </div>
    </div>
    </div>
    <!-- REFERENCE SECTION START -->
    <div class="section pt-100 pb-100">
        <div class="container">
            <div class="references-block">
                <h2>References:</h2>
                <ul>
                    <li>Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(12)1801-1812.</li>              
                    <li>Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7)807-825.</li>
                    <li>Dismukes WE, et al. Am J Med. 1992;93(5):489-497.</li>
                    <li>Patterson TF, et al. Clin Infect Dis. 2016;63(4):433-442.</li>
                    <li>Tsubura E, et al. Kekkaku. 1997;72:557-64.</li>
                    <li>Agarwal R, et al. Mycoses. 2013;56(5):559-570.</li>
                    <li>Denning D, et al. Clin Infect Dis 2003;37(S3): S265–80.</li>
                    <li>Dupont B, J Am Acad Dermatol 1990;23:607–14.</li>
                    <li>Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res. 2014;132(2):195-204.</li>
                    <li>Centers for Disease Control and Prevention. Symptoms of histoplasmosis. https://www.cdc.gov/fungal/diseases/histoplasmosis/symptoms.html. Accessed September 26, 2020.</li>
                    <li>Centers for Disease Control and Prevention. Symptoms of blastomycosis. https://www.cdc.gov/fungal/diseases/blastomycosis/symptoms.html. Accessed September 26, 2020.</li>
                    <li>Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7-14.</li>
                    <li>Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection. 2008;36(4)296-313.</li>
                    <li>Sporanox® Product Information. Janssen Pharmaceuticals, Inc. Titusville, NJ. May 2018.</li>
                    <li>Sporanox® oral solution Product Information. Janssen Pharmaceuticals, Inc. Titusville, NJ. Apr 2019.</li>
                    <li>Prentice AG, Glasmacher A. J Antimicrob Chemother. 2005;56(Suppl 1):i17-i22.</li>
                    <li>Abuhelwa AY, et al. Eur J Drug Metab Pharmacokinet. 2019;44(2):201-215.</li>
                    <li>Poirier JM, et al. Therapie. 1996;51(2):163-167.</li>
                    <li>TOLSURA® Product Information. Mayne Pharma. Greenville, NC. 12/2018.</li>
                    <li>Abuhelwa AY, et al. J Pharmacokinet Pharmacodyn. 2018;45(2):181-197.</li>
                    <li>Lindsay J, et al. Antimicrob Agents Chemother. 2018;62(12)e01723-18.</li>
                    <li>Gould IM, van der Meer JWM. Antibiotic Policies: Theory and Practice. New York: Kluwer Academic/Plenum, 2005.</li>
                    <li>Thompson GR, et al. Antimicrob Agents Chemother. 2020;64(8):e00400-20.</li>
                </ul>
            </div>
        </div>
    </div>
</div>
<!-- REFERENCE SECTION START -->
    
<div id="isi" class="section">
    <div class="container pb-100">
        <div class="row">
            <div class="col-md-12">
            <p>Indications and Important <br class="d-block d-lg-none d-md-none">  Safety Information 
                <span class="expand-collapse-isi">
                    <a href="#"><img class="fa fa-plus expand-isi" src="https://awareness.tolsura.com/l/153741/2021-04-12/442dl8/153741/1618221207YVr2k8j6/plus__icon.jpg" alt="plus icon"></a>
                    <a href="#"><img class="fa fa-minus collapse-isi expand-isi" src="https://awareness.tolsura.com/l/153741/2021-04-12/442dkx/153741/1618221206p3dCVT78/minus__icon.jpg" alt="minus icon"></a>
                </span>
                </p>
                <div class="warning-box">
                <p class="mb-0"><strong>BOXED WARNING</strong> <br /><strong>WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS</strong> </p>
                <ul class="bullet1 mb-1 mt-1">
                <li> » CONGESTIVE HEART FAILURE</li>
                </ul>
            <p class="mb-1 pl-3"><strong>TOLSURA can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. </strong>If signs or symptoms
        of congestive heart failure occur or worsen during administration of TOLSURA, reassess the benefit and risk of
        continuing treatment.</p>
            <ul class="bullet1">
                <li>  » DRUG INTERACTIONS</li>
            </ul>
            <ul class="bullet2">
                <li>Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with
                    TOLSURA because plasma concentrations of such drugs are increased, which may also increase or prolong both the
                    pharmacologic effects and/or adverse reactions to these drugs.</li>
                <li>Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and</li>
                <li>Co-administration with eligustat is contraindicated in subjects taking strong or moderate CYP2D6 inhibitors. </li>
                <li>Increased plasma concentrations of some of these drugs caused by co-administration with TOLSURA can lead to QT prolongation and/or ventricular tachyarrhythmias, including occurrences of torsades de pointes, a potentially fatal arrhythmia. </li>
            </ul>
        </div>
            
        </div>
        <div class="col-md-12">
            <p class="mb-0"><strong>Indications and Usage</strong> </p>
            <p >TOLSURA is an azole antifungal indicated for the treatment of the following fungal infections in <strong>immunocompromised and non-immunocompromised</strong> adult patients:</p>           
            <ul class="bullet2 ml-2">
                <li>Blastomycosis, pulmonary and extrapulmonary</li>
                <li>Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and</li>
                <li>Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy </li>
            </ul>
            <p class="mb-0 mb-2 mt-4"><strong>Limitations of Use:</strong></p>
                <p class="mb-0">TOLSURA is not indicated for the treatment of onychomycosis.</p>
                <p class="mb-0">TOLSURA is NOT interchangeable or substitutable with other itraconazole products.</p>
                <p class="mb-0 mb-2 mt-4"><strong>Contraindications</strong></p>
                <p class="mb-0">Co-administration with certain drugs that either affect metabolism of itraconazole or whose metabolism is affected by itraconazole Hypersensitivity to itraconazole</p>            
            <p class="mb-0 mb-2 mt-4"><strong>Warnings and Precautions</strong></p>
            <ul class="bullet2 ml-2">
                <li><strong>Hepatotoxicity:</strong> Serious hepatotoxicity, including liver failure and death, were reported with the use of itraconazole. Discontinue treatment if signs of liver dysfunction occur</li>
                <li><strong>Cardiac Dysrhythmias:</strong> Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using certain drugs that are metabolized by human CYP450 enzymes concomitantly with oral itraconazole and/or other CYP3A4 inhibitors.</li>
                <li><strong>Peripheral Neuropathy:</strong> This has been reported in patients on long-term therapy with itraconazole. Monitor and promptly evaluate neurologic symptoms </li>
                <li><strong>Hearing loss:</strong> Reversible or permanent hearing loss has been reported in patients. Discontinue treatment if hearing loss occurs </li>
            </ul>
            <p class="mb-0 mb-2 mt-4"><strong>Adverse Reactions</strong></p>
            <p class="mb-4">Most common adverse reactions (incidence ≥ 1%) are nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, hypertension, abnormal hepatic function, abdominal pain, dizziness, hypokalemia, anorexia, malaise, decreased libido, somnolence, albuminuria, and impotence.</p>
            <p class="mb-4"><strong>To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at <a href="tel:+18448258500">1-844-825-8500</a> or the FDA at 1-800-FDA-1088 or <a target="_blank" href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program"><u>www.fda.gov/medwatch.</u></a></strong></p>
            <p class="mb-0"><strong>For more information, please see full <a class="underline" target="_blank" href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=306352d1-9d5a-49ad-b72d-893b99546861&audience=professional"><u>Prescribing Information and Patient Information Leaflet.</u> </a></strong></p>
            </div>
        </div>
    </div>
</div>
<!-- ISI BLOCK END -->

<!-- FOOTER START -->
<footer>
    <div class="container">
        <div class="row">
            <div class="col-lg-3">
                <a href="#" class="footer__logo mb-lg-0 mb-4">
                    <img src="assets/img/TOLSURA_DARK_LOGO.png" alt="Tolsura">
                </a>
            </div>
            <div class="col-lg-5">
                <div class="footer__links mb-lg-0 mb-4">
                    <ul>
                        <li><a href="#">HOME</a></li>
                        <li><a href="#">INFECTIONS OVERVIEW</a></li>
                        <li><a href="#">ABOUT TOLSURA</a></li>
                        <li><a href="#">BENEFITS OF TOLSURA</a></li>
                        <li><a href="#">SAFETY</a></li>
                        <li><a href="#">DOSING</a></li>
                        <li><a href="#">SAVINGS</a></li>
                    </ul>
                </div>
            </div>
            <div class="col-lg-4">
                <div class="customer__service mb-4">
                    Customer Service <div class="d-block"><a href="tel:+18003448661">+1 800 344 8661</a></div>
                </div>
                <div class="address mb-4">
                    1240 Sugg Parkway, Greenville, NC 27834
                </div>
                <div class="medical__info mb-lg-3 mb-4">
                    Medical Information & Adverse Drug Events Reporting
                </div>
                <div class="report">
                    To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at <a href="tel:+18448258500">1-844-825-8500</a> or the FDA at <a href="tel:+1800FDA1088">1-800-FDA-1088</a> or <a href="http://www.fda.gov/medwatch" target="_blank" >www.fda.gov/medwatch</a>.
                </div>
            </div>
        </div>
        <div class="footer__bottom pt-150">
            <div class="row">
                <div class="col-12">
                    <div class="social__icon">
                        <ul>
                            <li><a href="#"><img src="assets/img/Icons_brand_twitter.svg" alt="Twitter"></a></li>
                            <li><a href="#"><img src="assets/img/Icons_brand_facebook.svg" alt="Facebook"></a></li>
                        </ul>
                    </div>
                </div>
                <div class="col-12">
                    <div class="footer__copyright">
                        <div class="row">
                            <div class="col-lg-6">
                                <div class="d-flex">
                                    <div class="copyright__text">© 2021 <a href="https://www.maynepharma.com/" target="_blank">Mayne Pharma</a>. All Rights Reserved.</div>
                                    <div class="pm__tool">PM-US-TOL-0002. 01/19</div>
                                </div>
                            </div>
                            <div class="col-lg-6">
                                <ul class="float-lg-right">
                                    <li><a href="https://www.maynepharma.com/privacy-policy/" target="_blank">Privacy Policy</a></li>
                                    <li><a href="https://www.maynepharma.com/terms-and-conditions/" target="_blank">Terms of Use</a></li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</footer>
<!-- FOOTER END -->


<!-- JS Script -->
<script src="assets/js/jquery-3.5.1.min.js"></script>
<script src="assets/js/bootstrap.min.js"></script>
<script src="assets/js/lazysizes.min.js"></script>
<script src="assets/js/ls.bgset.min.js"></script>
<script src="assets/js/custom.js"></script>
</body>
</html>
